Naval Daver
纳瓦尔·达维尔
MD
Professor, Department of Leukemia白血病科教授
👥Biography 个人简介
Leading investigator in targeted and immune-based therapies for AML at MD Anderson. Defined the clinical utility of FLT3 inhibitors and venetoclax-based combinations, driving major improvements in response rates for relapsed and frontline AML.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FLT3 Inhibitor Combinations
Pioneered combinations of FLT3 inhibitors with standard chemotherapy and novel backbones, substantially improving outcomes for FLT3-mutant AML patients in frontline and salvage settings.
Venetoclax-Based AML Regimens
Led trials integrating venetoclax with hypomethylating agents and other targeted agents, establishing regimens now widely adopted for older and unfit AML patients.
Representative Works 代表性著作
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in AML
Nature Medicine (2019)
Elucidated mechanisms underlying venetoclax/azacitidine efficacy in AML, explaining selective activity against leukemia stem cells and guiding rational combination strategies.
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD AML
The Lancet Oncology (2021)
Phase III trial showing quizartinib survival benefit in FLT3-ITD AML, supporting regulatory approval and establishing FLT3 inhibition as standard salvage therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
Gail Roboz
Weill Cornell Medicine / NewYork-Presbyterian Hospital
关注 纳瓦尔·达维尔 的研究动态
Follow Naval Daver's research updates
留下邮箱，当我们发布与 Naval Daver（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment